Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 4/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3741812 | 1.00 | CACNA1G (0.53) | CACNA1GCACNA1HCYP2D6CYP3A4OPRM1 | |
| SCHEMBL3752436 | 0.92 | CACNA1G (0.50) | CACNA1GCACNA1HCYP2D6CYP3A4OPRM1 | |
| SCHEMBL3633277 | 0.92 | CACNA1G (0.50) | CACNA1GCACNA1HCYP2D6CYP3A4OPRM1 | |
| SCHEMBL4681879 | 0.90 | CACNA1G (0.44) | CACNA1GCACNA1HCYP2D6CYP3A4OPRM1 | |
| SCHEMBL3639898 | 0.89 | C5AR1 (0.52) | CACNA1GCACNA1HCYP2D6CYP3A4C5AR1 | |
| SCHEMBL3748046 | 0.89 | C5AR1 (0.52) | CACNA1GCACNA1HCYP2D6CYP3A4C5AR1 | |
| SCHEMBL3637418 | 0.87 | CYP3A4 (0.47) | CACNA1GCACNA1HCYP2D6CYP3A4OPRM1 | |
| SCHEMBL13980437 | 0.87 | CYP3A4 (0.47) | CACNA1GCACNA1HCYP2D6CYP3A4OPRM1 | |
| SCHEMBL3748470 | 0.85 | OPRL1 (0.48) | CACNA1GCACNA1HCYP2D6CYP3A4OPRM1 | |
| SCHEMBL3748474 | 0.85 | OPRL1 (0.48) | CACNA1GCACNA1HCYP2D6CYP3A4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | disclosed |
| EP-2155676-A2 | COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS | Commissariat à l'Energie Atomique (FR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008146172-A2 | COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-12-04 | — | — | WO | disclosed |
| EP-1997805-A1 | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans | Commissariat à l'Energie Atomique (FR) | 2008-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | ABCB11, TPP1, ABCB1 | CACNA1G 3265/4885CACNA1H 3713/4885CYP2D6 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.